SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Take-Two is drawing attention as its shares sell off ahead of GTA VI, with traders debating whether launch expectations are already priced in and raising concerns about a possible game-build leak, PC-release timing, and the later arrival of online features. Others view the decline as a buying opportunity, arguing that strong demand for the blockbuster release and its future monetization could support the company.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnsons sharp decline after its quarterly results is driving discussion: adjusted results and full-year guidance beat expectations, but sluggish MedTech growth and a steep reported-earnings drop tied partly to a talc-litigation charge weighed on the stock. Traders are divided between viewing the selloff as an overreaction and buying the dip, and worrying about the valuation, device business and ongoing litigation exposure.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealths quarterly earnings beat and raised profit outlook, supported by improved medical-cost performance, are driving attention. Traders are divided after the initial gains faded: bulls see evidence of a turnaround, while others question the quality of the results and point to medical-cost concerns as reasons the stock failed to hold its rise.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS is drawing attention ahead of the anticipated final analysis of its Phase 3 REGAL trial of GPS in AML, with traders focused on the delayed 80th-event update and the companys quiet period. Heavy call-option activity and a recent share-price move have fueled speculation about a data leak, short squeeze, or potential buyout, but none of those explanations is confirmed.

Bumble, Inc. engages in the provision of online dating services. It operates through the following geographical segments: United States and Rest of the World. The company was founded by Whitney Wolfe Herd in 2014 and is headquartered in Austin, TX.

Bumble Inc - Ordinary Shares - Class A

Bumble Inc

Bumbles shares surged after it agreed to an all-cash take-private acquisition by Ithaca Holdings, with shareholders set to receive a substantial premium. Traders are debating whether the deal price caps further gains, while some speculate about a squeeze or a competing offer; completion remains subject to customary conditions.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is under pressure from concerns that Chinese chipmaker CXMTs planned server-memory architecture could intensify competition, alongside a broader semiconductor selloff tied to AI-spending worries. Traders debate whether Chinese supply could pressure memory pricing or remains a limited near-term threat to premium HBM, with some viewing the decline as overdone and buying the dip.

Applied Materials, Inc. engages in provision of materials engineering solutions used to produce semiconductors. The firm also focuses on design, development, production, and servicing of the critical wafer fabrication tools used for customers to manufacture semiconductors. It operates through the following segments: Semiconductor Systems and Applied Global Services (AGS). The Semiconductor Systems segment includes designing, development, manufacturing and sale of equipment used to fabricate semiconductor chips referred to as integrated circuits. The AGS segment engages in provision of services, spares, and factory automation software to customer fabrication plants globally. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

AMAT is under pressure after traders reacted poorly to its investor-day growth outlook and discussion of AI-driven expansion and the EPIC Center, amid weakness across semiconductor-equipment stocks. The community is split between calling the selloff an overreaction and worrying that high AI and capex expectations leave room for further downside; long-term bulls point to sustained wafer-fab demand.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Digitals proposed zero-coupon convertible note offering has weighed on shares, with traders focused on potential dilution, noteholder hedging, and the timing of the financing. Some see the capital as a way to fund Barber Lake and the AI data-center expansion on favorable terms, while others worry about added shareholder dilution and financing risk.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigettis $100 million U.S. government funding agreement and minority equity stake remain a central topic, with bulls seeing strategic backing for its superconducting quantum-computing work and skeptics noting the deal was already known and may involve dilution. Debate also focuses on the companys high valuation, limited commercial progress, and volatile trading alongside other quantum stocks.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm is drawing attention amid the AI-driven CPU demand story, particularly expectations that agentic AI and data-center workloads could boost demand for Arm-based designs and its AGI CPU. Traders remain divided after sharp swings: bulls see long-term AI infrastructure growth, while bears cite stretched valuation and concerns about AI spending and a broader semiconductor pullback.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$SLS 
One thing is for sure , JnJ will be watching Fox News. 

As they often “like” posts on linked in . They are aware of the appearance next week.

10xorbust

Allan Kristensen

Ludo

Brandon Skelton

Blockchainsaw

상후니

Ehrenhardt

Brian V

C. H.

John-Mark

James

BigSkyBigMoney

Adam Roberts

J Mattila

Jimmy2020

shan

Buffet87

Chessdoc

Gutshot71

Charles ford

Rasmus97

Stephen

Bob Zoo

StockTwits for iOS

 
One thing is for sure , JnJ will be watching Fox News. 

As they often “like” posts on linked in . They are aware of the appearance next week.

Nick

@WolfOfWillowick JNJ will not be watching Fox New. What are you talking about? They aren&#39;t retail investors.

StockTwits Web

 JNJ will not be watching Fox New. What are you talking about? They aren't retail investors.

@VinDoesStocks 
Did you read what I said?
Have you noticed how many times they “like” a Sterg post in Linked in ?

And that’s exactly why they would watch. Because they are not retail. They are a large company with BO power.

 
Did you read what I said?
Have you noticed how many times they “like” a Sterg post in Linked in ?

And that’s exactly why they would watch. Because they are not retail. They are a large company with BO power.

@WolfOfWillowick It doesn&#39;t matter how far ahead we look; the data isn&#39;t out yet, and we don&#39;t know if the drug will work. They want to see the data first this means nothing.

 It doesn't matter how far ahead we look; the data isn't out yet, and we don't know if the drug will work. They want to see the data first this means nothing.

@WolfOfWillowick No company would realistically acquire a drug without evaluating the clinical data. There is nothing that indicates this drug works without data.

 No company would realistically acquire a drug without evaluating the clinical data. There is nothing that indicates this drug works without data.

@VinDoesStocks I never said they’d acquire them w/o data. 

I said they’re aware of the Fox Appearance. Dont twist words.

 I never said they’d acquire them w/o data. 

I said they’re aware of the Fox Appearance. Dont twist words.

@WolfOfWillowick I don&#39;t think the drug will work so the timeline won&#39;t matter. No peptide vaccine has ever successfully crossed the finish line to treat Acute Myeloid Leukemia (AML) because the disease replicates far too quickly, routinely overwhelming a patient&#39;s immune response before T-cells can even deploy. While bulls view the heavily delayed 80th event as proof of the drug&#39;s efficacy, it’s highly likely a statistical mirage caused by a vastly improved Best Available Therapy (BAT) control arm. Modern leukemia supportive care has advanced significantly since the trial&#39;s historical baseline was set. If the control arm patients are the ones driving this survival extension, the trial will easily miss its aggressive Hazard Ratio target and in the eyes of the FDA, a statistical miss is a total failure, completely flattening the stock&#39;s current premium valuation.

 I don't think the drug will work so the timeline won't matter. No peptide vaccine has ever successfully crossed the finish line to treat Acute Myeloid Leukemia (AML) because the disease replicates far too quickly, routinely overwhelming a patient's immune response before T-cells can even deploy. While bulls view the heavily delayed 80th event as proof of the drug's efficacy, it’s highly likely a statistical mirage caused by a vastly improved Best Available Therapy (BAT) control arm. Modern leukemia supportive care has advanced significantly since the trial's historical baseline was set. If the control arm patients are the ones driving this survival extension, the trial will easily miss its aggressive Hazard Ratio target and in the eyes of the FDA, a statistical miss is a total failure, completely flattening the stock's current premium valuation.

@VinDoesStocks 

You are completely off topic. 

I made a comment about JnJ aware of Fox. 

Do you have ADHD or something ?!?!

 

You are completely off topic. 

I made a comment about JnJ aware of Fox. 

Do you have ADHD or something ?!?!

@WolfOfWillowick We&#39;re talking about SLS.